Preclinical data demonstrated that targeting LRRC15 with the antibody–drug conjugate ABBV-085 produced substantial anti-tumor effects in LRRC15-positive soft-tissue sarcoma (STS) models [112]. This evidence concerns the gene LRRC15 and telomere syndrome.